{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:09:32Z","timestamp":1774368572800,"version":"3.50.1"},"reference-count":183,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2021,6,3]]},"DOI":"10.1080\/17512433.2021.1917376","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T22:08:56Z","timestamp":1620425336000},"page":"687-701","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Treatment challenges in adult female acne and future directions"],"prefix":"10.1080","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-8241","authenticated-orcid":false,"given":"Edileia","family":"Bagatin","sequence":"first","affiliation":[{"name":"Universidade Federal De S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-177X","authenticated-orcid":false,"given":"Marco Alexandre Dias da","family":"Rocha","sequence":"additional","affiliation":[{"name":"Universidade Federal De S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-3837","authenticated-orcid":false,"given":"Thais Helena Proen\u00e7a","family":"Freitas","sequence":"additional","affiliation":[{"name":"Santa Casa Medical and Hospital School, Dermatology Clinic, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-6890","authenticated-orcid":false,"given":"Caroline Sousa","family":"Costa","sequence":"additional","affiliation":[{"name":"Discipline of Dermatology - Universidade Federal Do Piau\u00ed","place":["Teresina, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"issue":"1","key":"e_1_3_5_3_1","first-page":"37","article-title":"Emerging issues in adult female acne","volume":"10","author":"Zeichner JA","year":"2017","unstructured":"Zeichner JA, Baldwin HE, Cook-Bolden FE, et al. Emerging issues in adult female acne. J Clin Aesthet Dermatol. 2017;10(1):37\u201346.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61729-2"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S55832"},{"issue":"4","key":"e_1_3_5_6_1","first-page":"577","article-title":"Prevalence of facial acne in adults","volume":"41","author":"Goulden V","year":"1999","unstructured":"Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577\u2013580.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00357.x"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S137794"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.045"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12061"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02979.x"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12757"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-014-1482-6"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2016.63880"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14998"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1602"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.06.060"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.9638"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2014.26.1.11"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00450"},{"key":"e_1_3_5_21_1","first-page":"1","article-title":"The influence of the exposome on acne","volume":"30","author":"Dr\u00e9no B","year":"2018","unstructured":"Dr\u00e9no B, Bettoli V, Araviiskaia E, et al. The influence of the exposome on acne. J Eur Acad Dermatol Venereol. 2018;30:1\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16119"},{"issue":"5","key":"e_1_3_5_23_1","first-page":"1111","article-title":"Evidence for increase androsterone metabolism in some normoandrogenic women with acne","volume":"76","author":"Carmina E","year":"1993","unstructured":"Carmina E, Lobo RA. Evidence for increase androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab. 1993;76(5):1111\u20131114.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(01)01701-0"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962005000400011"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2004.05.007"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37559"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_500_19"},{"issue":"6","key":"e_1_3_5_29_1","first-page":"670","article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","volume":"15","author":"Lortscher D","year":"2016","unstructured":"Lortscher D, Admani S, Satur N, et al. Hormonal contraceptives and acne: a retrospective analysis of 2147 patients. J Drugs Dermatol. 2016;15(6):670\u2013674.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625180701548040"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev221"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.10.003"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04214.x"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.95450"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13664"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361571"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361570"},{"key":"e_1_3_5_38_1","first-page":"247","article-title":"Acne: a new model of imune-mediated chronic inflammatory skin disease","volume":"150","author":"Antiga E","year":"2015","unstructured":"Antiga E, Verdelli A, Bonciani D, et al. Acne: a new model of imune-mediated chronic inflammatory skin disease. G Ital Dermatol Venereol. 2015;150:247\u2013254.","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871528113666140606110024"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13190"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087011"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0558-5"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.1.48"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62715-3"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16099"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1989.tb00930.x"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb02521.x"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246015"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155598442773"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00540020"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00839.x"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020880005846"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-006-0063-3"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14585"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.10.004"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205009"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12340"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13030-020-00190-y"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13757"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361572"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1600-0"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/brv.12579"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.076"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.078"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12497"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3367"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20177003"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.4.481"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.11.001"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2015.02.001"},{"issue":"8","key":"e_1_3_5_71_1","first-page":"962","article-title":"Efficacy and safety of once-daily Dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Eichenfield LF","year":"2016","unstructured":"Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily Dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962\u2013969.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"e_1_3_5_72_1","first-page":"1084","article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older","volume":"17","author":"Tyring SK","year":"2018","unstructured":"Tyring SK, Kircik LH, Pariser DM, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084\u20131091.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"e_1_3_5_73_1","first-page":"924","article-title":"Anti-inflammatory dose doxycycline plus adapalene 0.3% and benzoyl peroxide 2.5% gel for severe acne","volume":"18","author":"Kircik LH","year":"2019","unstructured":"Kircik LH. Anti-inflammatory dose doxycycline plus adapalene 0.3% and benzoyl peroxide 2.5% gel for severe acne. J Drugs Dermatol. 2019;18(9):924\u2013927.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_74_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library Of Medicine; cited 2020 Feb 14. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04214639."},{"key":"e_1_3_5_75_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; cited 2020 Feb 14. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03653403"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15113"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.078"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15794"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.3977"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0465"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0464"},{"issue":"11","key":"e_1_3_5_82_1","first-page":"s6","article-title":"Oral tetracyclines and acne: a systematic review for dermatologists","volume":"19","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Hekmatjah J, Kircik LH. Oral tetracyclines and acne: a systematic review for dermatologists. J Drugs Dermatol. 2020;19(11):s6\u2013s13.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304120-00002"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20198203"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13776"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17591-0"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.553192"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0267-z"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.137.9.1252"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17099"},{"issue":"8","key":"e_1_3_5_92_1","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"2012","author":"Garner SE","year":"2012","unstructured":"Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;2012(8):CD002086.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2006.06053_suppx.x"},{"issue":"3","key":"e_1_3_5_94_1","first-page":"333","article-title":"Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study","volume":"17","author":"Leyden JJ","year":"2018","unstructured":"Leyden JJ, Sniukiene V, Berk DR, et al. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol. 2018;17(3):333\u2013338.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"e_1_3_5_95_1","first-page":"987","article-title":"Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","volume":"17","author":"Moore A","year":"2018","unstructured":"Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987\u2013996.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"e_1_3_5_96_1","first-page":"s5","article-title":"ARTICLE: a novel antibiotic just for acne","volume":"19","author":"Kircik LH","year":"2020","unstructured":"Kircik LH. ARTICLE: a novel antibiotic just for acne. J Drugs Dermatol. 2020;19(11):s5.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15048"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1796637"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.15026"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-019-00562-5"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.111"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2535"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2009.07238.x"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.09.023"},{"key":"e_1_3_5_105_1","unstructured":"RocheRoacutan (isotretino\u00edna) Produtos Roche Qu\u00edmicos e Farmac\u00eauticos S.A Available from: http:\/\/www.anvisa.gov.br\/datavisa\/filabula\/frmVisualizarBula.asp?pNuTransacao=14365632016&pIdAnexo=3212245"},{"issue":"11","key":"e_1_3_5_106_1","first-page":"CD009435","article-title":"Oral isotretinoin for acne","volume":"11","author":"Costa CS","year":"2018","unstructured":"Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018;11(11):CD009435. Tan J, Knezevic S, Boyal S, et al. Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120-150mg\/kg. J Cutan Med Surg. 2016;20(1):13-20","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.11.002"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12942"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.9364"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15089"},{"key":"e_1_3_5_111_1","first-page":"665","article-title":"Results of a phase 1152 III, double-blind, randomized, parallel-group, non-inferiority 1153 study evaluating the safety and efficacy of isotretinoin-Lidose 1154 in patients with severe recalcitrant nodular acne","volume":"13","author":"Webster GF","year":"2014","unstructured":"Webster GF, Leyden JJ, Gross JA. Results of a phase 1152 III, double-blind, randomized, parallel-group, non-inferiority 1153 study evaluating the safety and efficacy of isotretinoin-Lidose 1154 in patients with severe recalcitrant nodular acne. J Drugs Dermatol. 2014;13:665\u2013670.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962010000300006"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15668"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1159\/000057887"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3091"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb03336.x"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.113720"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2014.888079"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2016.1172234"},{"key":"e_1_3_5_120_1","doi-asserted-by":"crossref","unstructured":"Etminan M Bird ST Delaney JA et al. Isotretinoin and risk for inflammatory bowel disease: a nested 1250 case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149:216\u2013220.","DOI":"10.1001\/jamadermatol.2013.1344"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000496"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.303"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.042"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1416"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.028"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03933.x"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12170"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.09.001"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2077"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001166"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2018.1444775"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12544"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000353"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13317"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2012.02460.x"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22711"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001546"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.768758"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2016.12.007"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.03.004"},{"issue":"4","key":"e_1_3_5_141_1","first-page":"2","article-title":"The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"Van Vloten WA","year":"2002","unstructured":"Van Vloten WA, Van Haselen CW, Van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4):2\u201315.","journal-title":"Cutis"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00059-8"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318187e1c5"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.2.7804"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1572546"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-1-8"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003880"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.5070\/D3245040035"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.051"},{"key":"e_1_3_5_150_1","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","volume":"7","author":"Arowojolu AO","year":"2012","unstructured":"Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31825194ca"},{"issue":"6","key":"e_1_3_5_152_1","first-page":"391","article-title":"European expert group on oral antibiotics in acne. European recommendations on the use of oral antibiotics for acne","volume":"14","author":"Dr\u00e9no B","year":"2004","unstructured":"Dr\u00e9no B, Bettoli V, Ochsendorf F, et al. European expert group on oral antibiotics in acne. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391\u2013399.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12472325"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0245-x"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-1-208"},{"key":"e_1_3_5_156_1","first-page":"858p","volume-title":"Comprehensive dermatologic drug therapy","author":"Wolverton SE","year":"2021","unstructured":"Wolverton SE, Wu JJ. Comprehensive dermatologic drug therapy. 4th ed. Amsterdam, Netherlands: Elsevier; 2021. p. 858p.","edition":"4"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.05.127"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2016.12.002"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.93.1.137"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105557"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.036"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16302"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_249_17"},{"key":"e_1_3_5_164_1","unstructured":"Cyproterone Article-31 referral - Restrictions in use of cyproterone due to meningioma risk. Last updated: 20\/05\/2020 EMA\/147755\/2020."},{"issue":"3","key":"e_1_3_5_165_1","first-page":"37","article-title":"Oral Spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience","volume":"5","author":"Kim GK","year":"2012","unstructured":"Kim GK, Del Rosso JQ. Oral Spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol. 2012;5(3):37\u201350.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.2147\/OAJC.S85543"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13497"},{"issue":"2","key":"e_1_3_5_168_1","first-page":"18","article-title":"Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and\/or functional integrity of the epidermal barrier?","volume":"6","author":"Thiboutot D","year":"2013","unstructured":"Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and\/or functional integrity of the epidermal barrier? J Clin Aesthet Dermatol. 2013;6(2):18\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_169_1","first-page":"32","article-title":"Over-the-counter acne treatments: a review","volume":"5","author":"Decker A","year":"2012","unstructured":"Decker A, Graber EM. Over-the-counter acne treatments: a review. J Clin Aesth Dermatol. 2012;5:32\u201340.","journal-title":"J Clin Aesth Dermatol"},{"issue":"12","key":"e_1_3_5_170_1","first-page":"19","article-title":"The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection","volume":"6","author":"Del Rosso JQ","year":"2013","unstructured":"Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection. J Clin Aesthet Dermatol. 2013;6(12):19\u201327.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13579"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354886"},{"issue":"9","key":"e_1_3_5_173_1","first-page":"1104","article-title":"Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves the tolerability of topical tretinoin 0.05%: a randomized, investigator-blinded, split face study","volume":"11","author":"Schorr ES","year":"2012","unstructured":"Schorr ES, Sidou F, Kerrouche N. Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves the tolerability of topical tretinoin 0.05%: a randomized, investigator-blinded, split face study. J Drugs Dermatol. 2012;11(9):1104\u20131107.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12720"},{"issue":"3","key":"e_1_3_5_175_1","first-page":"18","article-title":"Moisturizers and ceramide-containing moisturizers may offer concomitant therapy with benefits","volume":"7","author":"Lynde CW","year":"2014","unstructured":"Lynde CW, Andriessen A, Barankin B, et al. Moisturizers and ceramide-containing moisturizers may offer concomitant therapy with benefits. J Clin Aesthet Dermatol. 2014;7(3):18\u201326.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-017-1795-3"},{"issue":"9","key":"e_1_3_5_177_1","first-page":"CD007917","article-title":"Light therapies for acne","volume":"9","author":"Barbaric J","year":"2016","unstructured":"Barbaric J, Abbott R, Posadzki P, et al. Light therapies for acne. Cochrane Database Syst Rev. 2016;9(9):CD007917.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"e_1_3_5_178_1","first-page":"881","article-title":"Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist","volume":"54","author":"Celasco G","year":"2004","unstructured":"Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881\u2013886.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10332.x"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00481-w"},{"key":"e_1_3_5_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.087"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1080\/gye.16.1.63.66"},{"key":"e_1_3_5_183_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01186"},{"key":"e_1_3_5_184_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13096"},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0345-x"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2021.1917376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:05:23Z","timestamp":1772762723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2021.1917376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":183,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,3]]}},"alternative-id":["10.1080\/17512433.2021.1917376"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2021.1917376","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}